Vyant Bio, Inc. (VYNT)
Vyant Bio, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cherry Hill, NJ, US. The stock last traded at $0.19, up 7.78% on the session, giving a market capitalisation of $0. On trailing twelve-month figures it carries a trailing P/E of -0.05, a net margin of -3406.9%. Its beta of 0.56 implies it has historically moved less than the broad market.
Vyant Bio, Inc. is a biotechnology company focused on identifying treatments for intricate neurological conditions, including both neurodevelopmental and neurodegenerative disorders. The firm leverages a sophisticated central nervous system (CNS) drug discovery platform that integrates human-derived brain organoid models, high-throughput biological screening, and machine learning. Their primary goal is to pinpoint novel or existing small molecule drug candidates for rare genetic CNS diseases like Rett Syndrome, CDKL5 deficiency disorders, and hereditary forms of Parkinson's disease. Additionally, Vyant Bio, Inc. maintains a collaborative agreement specifically for the discovery of Parkinson's Disease therapies. The company's headquarters are located in Cherry Hill, New Jersey.
Vyant Bio, Inc. is most often compared with the following Healthcare names: